Literature DB >> 32114600

Assessment of obsessive-compulsive disorder comorbidity and obsessive-compulsive symptom dimensions in patients with schizophrenia.

Ahmet Kokurcan1, Yasir Şafak.   

Abstract

OBJECTIVES: To assess obsessive-compulsive disorder (OCD) comorbidity and obsessive-compulsive symptom (OCS) dimensions in patients with schizophrenia.
METHODS: This cross-sectional study included 300 patients with schizophrenia who were applied to the to the Outpatient Psychiatry Clinic of Health Sciences University Dışkapı Yıldırım Beyazıt Training and Research Hospital,  Ankara, Turkey between July and December 2018. Data collection forms created by researchers were applied to the individuals. Obsessive-compulsive symptom were assessed with the Yale-Brown Obsessive Compulsive Scale (YBOCS) and the Dimensional Obsessive Compulsive Scale (DOCS).
RESULTS: The OCD prevalence was 17% (n=50) in the whole group while 10% (n=24/250) of the patients without OCD had 8-15 points at YBOCS. One-way ANOVA test revealed that the patients with OCD showed more severe positive, negative, and depressive symptoms, and also had lower functionality compared to those without OCD (p less than 0.05). The most severe OCS dimension was unacceptable obsessional thoughts in the patients with OCD and OCS. The severity of unacceptable obsessional thoughts was positively correlated with the depressive symptom severity, and negatively correlated with onset age of OCD and insight level in Pearson correlation analysis.
CONCLUSION: Patients with schizophrenia should be evaluated for presence of the OCS/OCD comorbidity in clinical practice. In addition, dimensional assessment of OCS might provide a different viewpoint on the presence of OCS/OCD in schizophrenia.

Entities:  

Mesh:

Year:  2020        PMID: 32114600     DOI: 10.15537/smj.2020.3.24909

Source DB:  PubMed          Journal:  Saudi Med J        ISSN: 0379-5284            Impact factor:   1.484


  1 in total

1.  Impact of COVID-19 Pandemic on Prescribing of Long-Acting Injectable Antipsychotics for Schizophrenia: Results from a United States Prescriber Survey.

Authors:  Maryia Zhdanava; H Lynn Starr; Todor I Totev; Patrick Lefebvre; Aditi Shah; Kristy Sheng; Dominic Pilon
Journal:  Neuropsychiatr Dis Treat       Date:  2022-09-07       Impact factor: 2.989

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.